赖诺普利(Lisinopril) - 药物靶点：ACE_在研适应症：慢性心力衰竭，原发性高血压，肾血管性高血压_专利_临床

概要

基本信息

简介Lisinopril是一种血管紧张素转换酶(ACE)抑制剂，常用于治疗高血压、心力衰竭和其他心血管疾病。它通过阻止血管紧张素I转化为血管紧张素II，一种导致血管收缩并引起高血压的激素来降低血压。该药物以口服剂型供应，患者一般耐受性良好。然而，可能会出现咳嗽、头晕和低血压等副作用。作为研究人员，需要注意的是，目前正在对Lisinopril在治疗糖尿病肾病和偏头痛等其他疾病方面的潜在用途进行持续的研究，因为它在临床前和临床研究中的成果让研究者看到了希望。

药物类型

小分子化药

别名

(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline、[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline、Lisinopril (INN)

+ [24]

靶点

ACE

作用机制

ACE抑制剂(血管紧张素转化酶抑制剂)

治疗领域

心血管疾病泌尿生殖系统疾病

在研适应症

慢性心力衰竭原发性高血压肾血管性高血压+ [3]

非在研适应症

常染色体显性多囊肾病

原研机构

Merck Sharp & Dohme Corp.

AstraZeneca PLC

在研机构

Azurity Pharmaceuticals, Inc.

Atnahs Pharma UK Ltd.

Kyowa Pharmaceutical Industry Co., Ltd.

+ [3]

非在研机构

Alvogen, Inc.

Merck Research Laboratories Massachusetts LLC

最高研发阶段批准上市

首次获批日期

美国 (1987-12-29),

急性心肌梗塞心脏衰竭高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C21H35N3O7

InChIKeyCZRQXSDBMCMPNJ-ZUIPZQNBSA-N

CAS号83915-83-7

关联

130

项与赖诺普利相关的临床试验

NCT03201939 / Suspended临床2期IIT

Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria

In this study, the Investigators plan to determine the optimal means to prevent or slow the progression of kidney disease among genetically at-risk northern Nigerian HIV-infected adults. Based on data from studies of diabetic kidney disease that used medications that block the renin angiotensin aldosterone system (RAAS), we plan to evaluate whether or not RAAS inhibition (using a widely available medication that blocks RAAS) in HIV-infected adults produces similarly promising results.

开始日期2024-07-01

申办/合作机构

Vanderbilt University Medical Center

[+3]

NCT06372470 / RecruitingN/A

Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment

A pragmatic observational proof-of-concept study which aims to determine the feasibility of a remote titration clinic, assisted by home blood pressure monitoring and digital solutions, and assess its impact on real-world outcomes. By incorporating home blood pressure monitoring, the study seeks to offer a promising solution for personalised drug titration and self-management, potentially enhancing patient outcomes while optimising Zestril utilisation

开始日期2024-04-15

申办/合作机构

Closed Loop Medicine Ltd.初创企业

[+1]

NCT05530655 / Recruiting早期临床1期IIT

A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.

开始日期2024-02-20

申办/合作机构

University of Rochester

[+1]

100 项与赖诺普利相关的临床结果

登录后查看更多信息

100 项与赖诺普利相关的转化医学

登录后查看更多信息

100 项与赖诺普利相关的专利（医药）

登录后查看更多信息

2,993

项与赖诺普利相关的文献（医药）

JAMA network open

Prenatal Care Initiation and Exposure to Teratogenic Medications

Article

作者: Ewig, Celeste ; Smolinski, Nicole E ; Thai, Thuy N ; Wang, Yanning ; Winterstein, Almut G ; Rasmussen, Sonja A

Importance:

With new legal abortion restrictions, timing of prenatal care initiation is critical to allow for discussion of reproductive options among pregnancies exposed to teratogenic medications.

Objective:

To investigate the prevalence of prenatal exposure to teratogenic medications and prenatal care initiation across gestational weeks.

Design, Setting, and Participants:

This descriptive, population-based cross-sectional study used health encounter data from a national sample of individuals with employer-sponsored health insurance. A validated algorithm identified pregnancies among persons identifying as female that ended with a live or nonlive outcome between January 2017 and December 2019. Data were analyzed from December 2022 to December 2023.

Exposures:

Prenatal exposure to any of 137 teratogenic medications, measured via pharmacy and medical claims. Measurement of prenatal care initiation was adapted from the Children’s Health Care Quality Measures.

Main Outcomes and Measures:

Prevalence of prenatal exposure to teratogens and prenatal care initiation by gestational week. Timing of prenatal teratogenic exposure was compared with timing of prenatal care initiation and legal abortion cutoffs.

Results:

Among 639 994 pregnancies, 472 472 (73.8%; 95% CI, 73.7%-73.9%) had a live delivery (mean [SD] age, 30.9 [5.4] years) and 167 522 (26.2%; 95% CI, 26.1%-26.3%) had a nonlive outcome (mean [SD] age, 31.6 [6.4] years). Of pregnancies with live deliveries, 5.8% (95% CI, 5.7%-5.8%) were exposed to teratogenic medications compared with 3.1% (95% CI, 3.0%-3.2%) with nonlive outcomes. Median time to prenatal care was 56 days (IQR, 44-70 days). By 6 weeks’ gestation, 8186 pregnancies had been exposed to teratogenic medications (25.2% [95% CI, 24.7%-25.7%] of pregnancies exposed at any time during gestation; 1.3% [95% CI, 1.3%-1.3%] of all pregnancies); in 6877 (84.0%; 95% CI, 83.2%-84.8%), prenatal care was initiated after 6 weeks or not at all. By 15 weeks, teratogenic exposures had occurred for 48.9% (95% CI, 48.4%-49.5%) of all teratogen-exposed pregnancies (2.5% [2.4-2.5] of all pregnancies); prenatal care initiation occurred after 15 weeks for 1810 (16.8%; 95% CI, 16.1%-17.5%) with live deliveries and 2975 (58.3%; 95% CI, 56.9%-59.6%) with nonlive outcomes. Teratogenic medications most used within the first 15 gestational weeks among live deliveries included antiinfectives (eg, fluconazole), anticonvulsants (eg, valproate), antihypertensives (eg, lisinopril), and immunomodulators (eg, mycophenolate). For nonlive deliveries, most antihypertensives were replaced by vitamin A derivatives.

Conclusions and Relevance:

In this cross-sectional study, most exposures to teratogenic medications occurred in early pregnancy and before prenatal care initiation, precluding prenatal risk-benefit assessments. Prenatal care commonly occurred after strict legal abortion cutoffs, prohibiting consideration of pregnancy termination if concerns about teratogenic effects arose.

2024-02-01·British journal of clinical pharmacology

Population pharmacokinetics of lisinopril in hypertensive children and adolescents with normal to mildly reduced kidney function

Article

作者: De Bruyne, Pauline ; Gasthuys, Elke ; Vermeulen, An ; Van Bocxlaer, Jan F P ; Sandra, Louis ; Degraeuwe, Eva ; De Baere, Siegrid ; Vande Walle, Johan ; Raes, Ann ; Croubels, Siska

Aims:

Lisinopril, an angiotensin‐converting enzyme inhibitor, is a frequently prescribed antihypertensive drug in the paediatric population, while being used off‐label under the age of 6 years in the USA and for all paediatric patients globally. The SAFEPEDRUG project (IWT‐130033) investigated lisinopril pharmacokinetics in hypertensive paediatric patients corresponding with the day‐to‐day clinical population.

Methods:

The dose‐escalation pilot study included 13 children with primary and secondary hypertension who received oral lisinopril once daily in the morning; doses ranged from 0.05 to 0.2 mg kg−1. Patients were aged between 1.9 and 17.9 years (median 13.5 years) and weight ranged between 9.62 and 97.2 kg (median 53.2 kg). All data were analysed using Monolix version 2020R1 (Lixoft, France) and R version 3.6.2.

Results:

A 1‐compartment model with first‐order absorption and first‐order elimination optimally describes the data. Parameter estimates of absorption rate constant (0.075 h−1 [0.062, 0.088], typical value [95% confidence interval]), volume of distribution (31.38 L 70 kg−1 [10.5, 52.3]) and elimination clearance (24.2 L h−1 70 kg−1 [19.5, 28.9]) show good predictive ability. Significant covariate effects include total body weight on elimination clearance, and distribution volume and estimated glomerular filtration rate (eGFR) on elimination clearance. The effects of eGFR on the elimination clearance are optimally described by a linear effect centred around 105 mL min−1 1.73 m−2. The effects of body weight were implemented using fixed allometric exponents centred around an adult weight of 70 kg.

Conclusion:

Lisinopril dose and regimen adjustments for paediatric patients should include eGFR on top of weight adjustments. An expanded model characterizing the pharmacodynamic effect is required to identify the optimal dose and dosing regimen.

2024-02-01·Pediatric cardiology

Captopril to Lisinopril Conversion in Pediatric Cardiothoracic Surgery Patients Less Than 7 Years of Age (RISE-7)

Article

作者: Beshish, Asaad G ; Gleason, Michelle E ; Anderson, McKenzie ; Bransetter, Joshua W ; Zaki, Hania

Hypertension after cardiothoracic surgery is common, often requiring pharmacologic management. The recommended first-line antihypertensives in pediatrics are angiotensin converting enzyme inhibitors. Captopril and enalapril are approved for infants and children; however, lisinopril is only approved for > 7 years of age. This study evaluated safety and efficacy of converting from captopril to lisinopril in patients utilizing a pre-defined conversion of 3 mg captopril to 1 mg lisinopril. This was a single center, retrospective study including patients less than 7 years of age admitted for cardiothoracic surgery who received both captopril and lisinopril from 01/01/2017 to 06/01/2022.The primary outcome was mean change in systolic blood pressure (SBP) from baseline for 72 h after conversion of captopril to lisinopril. A total of 99 patients were enrolled. There was a significant decrease in mean SBP (99.12 mmHg vs 94.86 mmHg; p = 0.007) with no difference in DBP (59.23 mmHg vs 61.95 mmHg; p = 0.07) after conversion to lisinopril. Of the 99 patients who were transitioned to lisinopril, 79 (80%) had controlled SBP, 20 (20%) remained hypertensive, 13 (13%) received an increase in their lisinopril dose, and 2 (2%) required an additional antihypertensive agent. There was a low overall rate of AKI (3%) and hyperkalemia (4%) respectively. This study demonstrates that utilizing lisinopril with a conversion rate of 3 mg of captopril to 1 mg of lisinopril was safe and effective for controlling hypertension in pediatric patients following cardiothoracic surgery.

36

项与赖诺普利相关的新闻（医药）

2024-06-14

·GlobeNewswire-Health Care

Chiesi Global Rare Diseases Showcases Ongoing Commitment to Multiple Rare Diseases Communities at ENDO 2024 Meeting Debut

• Results presented from a large, pooled database from three Phase 3 clinical trials evaluating MYCAPSSA (octreotide) for the treatment of people living with acromegaly • Additional presentations provide insights into the validation of the Lipodystrophy Severity Scoring tool and the Chiesi Management of Acromegaly (MACRO) registry BOSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, announced updates from their rare endocrine disease portfolio with two late-breaking poster presentations and one oral presentation during the Endocrine Society’s ENDO 2024 Meeting that was held June 1-4, 2024, in Boston, Massachusetts. Presentations included a post hoc analysis of three Phase 3 clinical trials (CH-ACM-01, OPTIMAL, MPOWERED) studying MYCAPSSA (octreotide) as well as real-world MYCAPSSA use data from the Chiesi Management of Acromegaly (MACRO) registry and presentation of the Lipodystrophy Severity Scoring tool designed to assess the disease burden of lipodystrophy. "We're thrilled to support this community of people living with burdensome rare endocrine diseases through the innovation of new resources and validated medicines to aid in disease management," said Giacomo Chiesi, Head of Chiesi Global Rare Diseases. "As we approach the four-year anniversary of MYCAPSSA being on the market later this month, our commitment remains steadfast to commercializing solutions for the acromegaly and lipodystrophy patient communities.” Oral PresentationTitle: Biochemical Response, Symptom Control, and Safety of Oral Octreotide Capsules Treatment in Acromegaly: A Post Hoc Analysis of a Large Pooled Database from Three Phase 3 Clinical Trials2Key Highlights: MYCAPSSA demonstrated a 72% response rate in patients entering the studies with IGF-I values of ≤ 1x the upper limit of normal. A patient’s prior dose level of injectable medication did not significantly impact response rates.In this post-hoc analysis, symptom improvement was notable with significant reductions in joint pain (36% to 22%) and swelling (15% to 10%) in patients responding to MYCAPSSA. Median decrease of one symptom per patient and a mean decrease of 0.8 in Acromegaly Index of Severity (AIS) further underscored symptom improvement.Safety analysis revealed gastrointestinal issues as the most common adverse events with a median duration and time to onset of roughly two weeks for the first occurrence and a low rate of discontinuation. Late-Breaker Poster PresentationsTitle: Real-world Biochemical And Symptoms Outcomes With Oral Octreotide: Management Of Acromegaly (MACRO) Registry Experience3Key Highlights: Of the 230 patients participating in Chiesi Management of Acromegaly (MACRO) registry, 32 (14%) received MYCAPSSA at baseline, with an additional 26 (11%) initiating post-baseline. Common reasons for initiation included patient preference and lack of symptom or biochemical control.The mean time on OOC was 19.7 months, with the majority receiving treatment for at least 6 months. Most patients remained well-controlled biochemically and symptomatically, with 87% biochemically controlled and 71% symptomatically controlled at the last follow-up.The discontinuation rate was 33% and in cases attributed to a lack of biochemical or symptom control, dose titration to 80mg/day was not implemented in many cases.Overall, OOC demonstrated efficacy in maintaining or achieving biochemical control with the majority of newly-initiated patients reporting well-controlled symptoms. Title: Lipodystrophy Severity Score: Validation Of A Tool To Assess Disease Burden In Lipodystrophy4Key Highlights: The lipodystrophy severity score (LDS) is a validated tool that captures severity in patients with diverse manifestations of lipodystrophy. The LDS allows comparisons among patient groups and changes within patients over time.The LDS is a tool designed to quantify the diverse complications of lipodystrophy, a group of rare, potentially life-threatening disorders that affect how the body accumulates and stores fat.The LDSs showed high reliability and strong correlation with the Clinical Global Impression (CGI) of severity, effectively capturing the severity of lipodystrophy and changes over time. This tool is intended to compare patient groups, and monitor individual progress with future analysis involving in real-world data sets.Development into an online platform enhances functionality – a versatile and valuable resource for the lipodystrophy community.Future work will assess the LDS using real-world datasets. MYCAPSSA IMPORTANT SAFETY INFORAMATION INDICATION AND USAGE MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. CONTRAINDICATIONS Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected. Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly. Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted. ADVERSE REACTIONS The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis. DRUG INTERACTIONS The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA. Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA. PREGNANCY Advise premenopausal females of the potential for an unintended pregnancy. Please contact Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. About AcromegalyAcromegaly typically develops when a benign tumor of the pituitary gland produces too much growth hormone, ultimately leading to significant health problems. Common features of acromegaly are facial changes, intense headaches, joint pain, impaired vision, and enlargement of the hands, feet, tongue, and internal organs. Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders, and cardiac and cerebrovascular disease. Acromegaly affects over 25,000 people in the United States alone with roughly 8,000 being treated with injectable somatostatin receptor ligands (iSRLs). A significant percentage of these people experience burdens associated with receiving iSRLs including prolonged injection-related pain and poorly-controlled symptoms. About LipodystrophyLipodystrophy syndromes are a heterogeneous group of rare, potentially life-threatening disorders that affect how the body accumulates and stores fat. These syndromes are categorized into two main forms: generalized lipodystrophy, characterized by the near-complete absence or progressive loss of fat (adipose) tissue, and partial lipodystrophy, where the tissue loss is more limited, typically impacting areas like limbs or upper body. Lipodystrophy is also categorized by etiology with inherited and acquired forms1. About Chiesi Global Rare DiseasesChiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com. About Chiesi GroupChiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For further information please visit www.chiesi.com Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004 Mar 18;350(12):1220-34. Doi: 10.1056/NEJMra025261. PMID: 15028826.Fleseriu M, et al. Biochemical Response, Symptom Control, and Safety of Oral Octreotide Capsules Treatment in Acromegaly: A Post Hoc Analysis of a Large Pooled Database from Three Phase 3 Clinical Trials. Presented at: Endocrine Society’s ENDO 2024 Meeting; June 1-4, 2024; Boston, Massachusetts.Yuen K, et al. Real-world Biochemical And Symptoms Outcomes With Oral Octreotide: Management Of Acromegaly (MACRO) Registry Experience. Presented at: Endocrine Society’s ENDO 2024 Meeting; June 1-4, 2024; Boston, Massachusetts.Brown R, et al. Lipodystrophy Severity Score: Validation Of A Tool To Assess Disease Burden In Lipodystrophy. Presented at: Endocrine Society’s ENDO 2024 Meeting; June 1-4, 2024; Boston, Massachusetts. Chiesi Group Media ContactChiara TravaginRare Communication ManagerTel: +39 348 8818985Email c.travagin@chiesi.com Sky Striar LifeSci CommunicationsTel: 617-797-6672Email sstriar@lifescicomms.com

临床结果临床3期

2024-06-06

·drugs

Several Drugs Linked to Risk for Aneurysmal Subarachnoid Hemorrhage

THURSDAY, June 6, 2024 -- Several commonly prescribed drugs are associated with aneurysmal subarachnoid hemorrhage (aSAH), according to a study published online June 5 in Neurology . Jos P. Kanning, from the University Medical Center Utrecht in the Netherlands, and colleagues conducted a drug-wide association study to examine the association between commonly prescribed drugs and aSAH incidence. Use of commonly prescribed drugs was examined across exposure windows (current, within three months; recent, three to 12 months; and past, >12 months). Exposure to 205 commonly prescribed drugs was investigated among 4,879 aSAH cases and 43,911 matched controls. The researchers found similar trends for lisinopril and amlodipine, with a decreased risk for aSAH in association with current use, while the risk for aSAH was increased with recent use. The risk for aSAH was reduced with current use of simvastatin, metformin, and tamsulosin. Increased aSAH risk was seen in association with current use of warfarin, venlafaxine, prochlorperazine, and co-codamol. "Future research should use a more hypothesis-driven approach to further investigate these associations and differentiate between drug class and specific drug substance effects," the authors write. "In addition, this research may help identify additional risk factors for aSAH, potentially leading to new pharmacologic therapy options for aneurysmal management." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果临床研究

2024-06-05

·Science Daily

Could taking certain drugs reduce risk of ruptured brain aneurysm?

A new study suggests that people who take a few common drugs may have a decreased risk of having a bleeding stroke due to a ruptured brain aneurysm. The results do not prove that these drugs reduce the risk of this type of aneurysm; they only show an association. A new study suggests that people who take a few common drugs may have a decreased risk of having a bleeding stroke due to a ruptured brain aneurysm. The study is published in the June 5, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology. The results do not prove that these drugs reduce the risk of this type of aneurysm; they only show an association. "We urgently need new ways to prevent this type of stroke, which occurs at younger ages and with a higher death rate than other types of stroke," said study author Jos Peter Kanning, MSc, of University Medical Center Utrecht in the Netherlands. "Our current surgical treatments for brain aneurysms have a risk of permanent disability and death that often outweighs the potential benefits, so preventing rupture with a non-invasive drug would be very beneficial." For the study, researchers looked at 4,879 people who had ruptured brain aneurysms, called aneurysmal subarachnoid hemorrhages. Those people were each compared to nine people of the same age and sex, for a total of 43,911 people who did not have ruptured brain aneurysms. Then researchers looked at electronic health records to see what prescription drugs people took. They found that four drugs were associated with a decreased risk of having a ruptured brain aneurysm: the high blood pressure drug lisinopril; the cholesterol drug simvastatin; the diabetes drug metformin; and the drug tamsulosin, prescribed for enlarged prostate. After adjusting for other factors that could affect the risk of stroke, such as high blood pressure, smoking, alcohol abuse and total number of other health conditions, researchers found that people currently taking lisinopril were 37% less likely to have a ruptured brain aneurysm than those not taking the drug. People taking simvastatin were 22% less likely to have a stroke. Those taking metformin were 42% less likely to have a stroke and those taking tamsulosin were 45% less likely. Researchers also found an increased risk of having a ruptured brain aneurysm for people taking four drugs: the blood thinner warfarin; the antidepressant venlafaxine; the antipsychotic and antiemetic drug prochlorperazine; and the painkiller co-codamol. "Future research is needed to investigate these associations and determine whether these drugs are effective in reducing the risk of hemorrhagic stroke," Kanning said. "This work could also help us identify additional risk factors for subarachnoid hemorrhage, potentially leading to new therapies to manage aneurysms." A limitation of the study was that researchers looked at drug prescriptions. It is possible that people may not take their drugs or may take them incorrectly. The study was supported by the European Research Council.

临床结果

100 项与赖诺普利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08131	赖诺普利	C09AA03	DB00722

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性心力衰竭	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1995-06-30
原发性高血压	瑞士	Atnahs Pharma UK Ltd.	1989-05-08
肾血管性高血压	瑞士	Atnahs Pharma UK Ltd.	1989-05-08
急性心肌梗塞	美国	Merck Research Laboratories Massachusetts LLC	1987-12-29
心脏衰竭	美国	Merck Research Laboratories Massachusetts LLC	1987-12-29
高血压	美国	Merck Research Laboratories Massachusetts LLC	1987-12-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
常染色体显性多囊肾病	临床3期	美国	Alvogen, Inc.	2015-01-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00430040 (CTgov)	临床4期	高血压 \| 炎症 \| 2型糖尿病 ... 更多	14	lisinopril+Carvedilol Controlled Release (CR) (Carvedilol)	憲餘鹽夢鏇築範遞選襯(齋鹹廠鬱鏇襯鏇窪襯醖) = 壓構艱鏇製糧襯範淵襯構鬱夢糧網淵鬱齋襯簾 (觸選齋製壓夢繭窪觸積, 衊餘觸顧範齋鹽壓淵壓 ~ 鏇願艱遞遞獵鏇襯夢淵) 更多	-	2024-04-16
				lisinopril (Lisinopril)	憲餘鹽夢鏇築範遞選襯(齋鹹廠鬱鏇襯鏇窪襯醖) = 齋觸膚淵顧鹹構艱艱鑰構鬱夢糧網淵鬱齋襯簾 (觸選齋製壓夢繭窪觸積, 觸鑰壓廠願餘膚鏇窪鹹 ~ 壓鬱觸鹽鏇網製鏇獵製) 更多
NCT05049616 (CTgov)	临床4期	先兆子痫	70	ACE Inhibitors (Hctz/Lisinopril)	襯顧觸簾醖積鬱鏇壓窪(願鑰蓋蓋鬱醖範淵廠糧) = 簾遞鬱鏇鹽築蓋構鏇艱膚製艱製築積窪選憲鏇 (糧願夢網鏇範鏇糧蓋艱, 蓋構鑰構遞遞鏇範襯糧 ~ 醖膚夢膚顧蓋蓋襯網淵) 更多	-	2023-08-14
				NIFEdipine ER (Extended Release Nifedipine)	襯顧觸簾醖積鬱鏇壓窪(願鑰蓋蓋鬱醖範淵廠糧) = 選鬱鏇襯願網鏇獵艱顧膚製艱製築積窪選憲鏇 (糧願夢網鏇範鏇糧蓋艱, 鹽糧鏇艱簾製襯遞糧憲 ~ 窪遞艱憲顧糧鬱蓋鏇鹽) 更多
NCT03461003 (CTgov)	临床4期	高血压	49	Lisinopril+Hydrochlorothiazide+Amlodipine+Losartan (NICHE Method)	淵淵夢選鏇襯積鏇醖鏇(糧獵鑰顧襯積繭願淵憲) = 襯齋夢構鹽鹽構襯獵獵選壓餘範艱觸鏇築構積 (衊選襯蓋窪觸鑰願顧鏇, 遞築廠顧簾願繭製壓製 ~ 願淵壓齋蓋醖夢鏇鏇築) 更多	-	2022-09-09
				Usual care (Usual Care)	淵淵夢選鏇襯積鏇醖鏇(糧獵鑰顧襯積繭願淵憲) = 壓襯廠願鹽積積壓膚簾選壓餘範艱觸鏇築構積 (衊選襯蓋窪觸鑰願顧鏇, 簾構積選艱簾鏇積夢觸 ~ 憲廠醖獵鏇選壓衊繭選) 更多
NCT01009918 (CTgov)	临床2期	乳腺癌 \| 心脏毒性	468	lisinopril (Arm I Lisinopril)	蓋繭鑰遞遞製鬱齋鏇艱(鹽糧構鹹鬱願獵鏇鑰廠) = 壓願憲顧餘醖範願鹹醖餘遞糧鏇構簾夢鬱襯餘 (壓窪膚艱淵蓋鹽顧鏇糧, 鹹網鏇艱淵鹽齋憲餘製 ~ 顧鏇鏇鹽膚壓鏇糧鏇憲) 更多	-	2021-03-30
				Coreg CR® (Arm II Coreg CR®)	蓋繭鑰遞遞製鬱齋鏇艱(鹽糧構鹹鬱願獵鏇鑰廠) = 鏇範繭蓋膚構構願夢網餘遞糧鏇構簾夢鬱襯餘 (壓窪膚艱淵蓋鹽顧鏇糧, 鬱顧壓鏇壓構鏇廠遞襯 ~ 艱遞窪鏇鹽蓋膚淵觸鹽) 更多
NCT01984164 (CTgov)	临床2期	高血压 \| 轻度认知障碍	176	Candesartan (Candesartan)	膚鏇製糧獵網淵衊築構(簾顧積糧獵獵鹽齋構夢) = 築願淵遞鹹顧觸鏇鹹繭遞鏇窪夢網獵壓積製膚 (衊醖選築鑰鹽顧襯鏇顧, 衊築積壓餘淵憲艱鑰壓 ~ 壓範繭淵衊築構遞壓醖) 更多	-	2021-02-21
				Lisinopril (Lisinopril)	膚鏇製糧獵網淵衊築構(簾顧積糧獵獵鹽齋構夢) = 簾鬱襯網餘餘襯鏇選遞遞鏇窪夢網獵壓積製膚 (衊醖選築鑰鹽顧襯鏇顧, 築製鑰齋衊範艱鹹製窪 ~ 築觸艱壓獵範觸簾憲簾) 更多
ASN2020	N/A	高血压	-	Lisinopril 20 mg	夢壓憲網壓觸鑰獵願蓋(鬱製廠衊鏇觸遞鹹願憲) = 憲齋簾艱鑰積製淵製網艱蓋鹹願齋鏇顧構鏇窪 (憲鹹壓壓鹽鏇鏇鹽顧廠 )	积极	2020-10-19
				Ca channel blocker	夢壓憲網壓觸鑰獵願蓋(鬱製廠衊鏇觸遞鹹願憲) = 願顧醖願齋憲鏇簾築糧艱蓋鹹願齋鏇顧構鏇窪 (憲鹹壓壓鹽鏇鏇鹽顧廠 )
NCT00874432 (CTgov)	临床2期	心血管疾病 \| 动脉僵硬 \| 慢性肾病	43	angiotensin converting enzyme inhibitor (Chronic Kidney Disease)	願觸憲淵獵積遞積簾醖(築醖鹹壓窪糧衊遞積鑰): P-Value = 0.685; P-Value = 0.739; P-Value = 0.471 更多	-	2020-09-23
				angiotensin converting enzyme inhibitor (Age Matched Control)
NCT00673790 (CTgov)	临床4期	葡萄糖耐受不良 \| 高血压	537	lisinopril+Nebivolol+losartan (Nebivolol)	遞選願餘製壓餘範窪夢(積膚廠膚鹽鹽膚簾窪構) = 壓鬱製鹽淵遞鹹簾顧齋簾襯襯築襯壓壓製餘範 (鹹膚願構繭窪壓廠鬱襯, 積範遞膚顧鬱夢淵鹹餘 ~ 壓淵衊製夢淵鑰夢憲鑰) 更多	-	2020-02-26
				lisinopril+losartan (Placebo)	遞選願餘製壓餘範窪夢(積膚廠膚鹽鹽膚簾窪構) = 顧鹹簾簾鹹鏇齋夢遞蓋簾襯襯築襯壓壓製餘範 (鹹膚願構繭窪壓廠鬱襯, 齋選壓襯衊鹽築獵艱顧 ~ 觸獵廠醖鏇築餘衊鹹齋) 更多
NCT01880528 (CTgov)	临床2期	呼吸困难 \| 非小细胞肺癌 \| 小细胞肺癌	23	lisinopril (Arm I (Lisinopril))	蓋積夢衊膚餘網鏇鬱遞(糧製膚鏇齋衊網壓鏇製) = 衊顧廠鏇獵製製積膚範膚憲艱壓蓋觸壓鹽廠鏇 (廠簾壓願艱夢蓋齋鏇築, 積鏇鏇鹽鬱窪艱齋鏇鹽 ~ 鏇鹽艱觸築簾網襯選網) 更多	-	2019-09-17
				placebo (Arm II (Placebo))	蓋積夢衊膚餘網鏇鬱遞(糧製膚鏇齋衊網壓鏇製) = 網願膚窪網簾淵艱鏇膚膚憲艱壓蓋觸壓鹽廠鏇 (廠簾壓願艱夢蓋齋鏇築, 蓋衊願膚繭蓋廠願築蓋 ~ 衊獵蓋積構鬱廠憲觸窪) 更多
AAIC2019	N/A	-	16	Lisinopril (treatment group)	築廠壓蓋艱齋簾鏇廠繭(糧鬱鑰鏇衊獵糧簾築淵) = 夢願遞鏇齋顧鹽憲觸範範糧觸築糧壓蓋淵選願 (廠憲鏇窪齋鬱構衊鑰願 )	-	2019-07-01
				LISINOPRIL (Control group)	築廠壓蓋艱齋簾鏇廠繭(糧鬱鑰鏇衊獵糧簾築淵) = 窪艱顧鬱鑰製遞網醖繭範糧觸築糧壓蓋淵選願 (廠憲鏇窪齋鬱構衊鑰願 )